BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Nimotuzumab: Phase II ongoing

YM BioSciences disclosed in its fiscal 2Q11 earnings that it is evaluating whether to continue a pair of double-blind, placebo-controlled, international Phase II trials of nimotuzumab due to lagging recruitment targets. YM declined to disclose the current enrollment in the trials or its timeline for a decision on the trials. The biotech said it would instead focus on advanced trials involving partner Daiichi Sankyo, including a planned pivotal trial of nimotuzumab in gastric cancer....

Read the full 347 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >